We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

p38-MAPK

p38 mitogen-activated protein kinase (MAPK) inhibitors act on stress-activated kinases of the MAPK family. In 1994 p38 was described as a kinase phosphorylated on tyrosine after exposure of cells to bacterial endotoxin or hyperosmolarity. In the same year, a kinase targeted by pyridinyl imidazole compounds was shown to regulate the biosynthesis of inflammatory cytokines. Adezmapimod, also known as SB 203580, and SB 202190 belong to this pyridinyl imidazole class and inhibit p38α and p38β. Doramapimod binds an allosteric pocket that becomes accessible in an inactive conformation of the kinase, a binding mode reported in 2002. PH-797804 and ralimetinib dimesylate are further p38α inhibitors for studies of inflammatory and stress signaling.

1 Item

  • AL-8810
    Cat. No.
    A24200
    CAS No.
    246246-19-5

    AL-8810

    AL-8810 is a potent and selective antagonist of the prostaglandin F2α (PGF2α) receptor (FP receptor), with Ki values of 0.2 ± 0.06 μM in mouse 3T3 cells and 0.4 ± 0.1 μM in rat A7r5 cells. In addition to its antagonistic activity, AL-8810 also activates MAPK and ERK1/2 signaling pathways. It is commonly used in research related to elevated intraocular pressure (OHT) and primary open-angle glaucoma (POAG).

    In stock View Details
    1 mg
    $198.00
    5 mg
    $594.00
    All 4 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...